In a 60-year-old woman with a history of pancreatitis who cannot use glucagon-like peptide-1 (GLP-1) receptor agonists, what are the best weight-loss medications available in Canada?

Best Weight Loss Medications for a 60-Year-Old Woman with History of Pancreatitis in Canada

Given your history of pancreatitis and contraindication to GLP-1 receptor agonists, the best available weight loss medications in Canada are phentermine-topiramate ER, naltrexone-bupropion ER, and orlistat, with phentermine-topiramate ER likely offering the greatest weight loss efficacy among non-GLP-1 options.

Primary Medication Options

Phentermine-Topiramate ER (First-Line Alternative)

• This combination produces the most substantial weight loss among non-GLP-1 medications, with moderate-quality evidence supporting its use in adults with obesity or overweight with weight-related complications 1.
• The American Gastroenterological Association conditionally recommends this medication with lifestyle modifications for obesity management 1.
• Specific advantages for your profile:
  • Particularly beneficial if you have comorbid migraine headaches, as topiramate treats migraines 1.
  • Does not carry pancreatitis risk like GLP-1 receptor agonists 1.

Critical monitoring requirements:

• Blood pressure and heart rate must be monitored periodically while taking this medication 1.
• Avoid if you have cardiovascular disease history or uncontrolled hypertension 1.
• At 60 years old and post-menopausal, teratogenicity concerns with topiramate are not applicable 1.

Naltrexone-Bupropion ER (Second-Line Alternative)

• The AGA conditionally recommends this combination with lifestyle modifications for adults with obesity 1.
• Consider this option if you:
  • Are attempting smoking cessation 1.
  • Have comorbid depression 1.

Critical contraindications and monitoring:

• Absolutely avoid if you have a seizure disorder or are at risk for seizures 1.
• Cannot be used concomitantly with opiate medications 1.
• Blood pressure and heart rate require monitoring, especially during the first 12 weeks of treatment 1.

Orlistat (Third-Line Alternative)

• This is the most conservative option with the longest safety track record 1.
• Works through a different mechanism (lipase inhibitor) than other weight loss medications 1.
• Produces more modest weight loss compared to phentermine-topiramate ER or naltrexone-bupropion ER 1.
• Primary side effects are gastrointestinal (fatty stools, fecal urgency) rather than systemic 1.

Important Context About GLP-1 Receptor Agonists and Pancreatitis

While you've been advised to avoid GLP-1 receptor agonists due to your pancreatitis history, recent evidence suggests this concern may be overstated:

• Large meta-analyses of clinical trial data do not support a class-wide increased risk of pancreatitis with GLP-1 receptor agonists 2.
• When stratified by background medication use, the pancreatitis risk with GLP-1 receptor agonists is not statistically significant 3.
• Early clinical trials suggested a slightly increased risk, but this has not been confirmed in more recent comprehensive analyses 2, 3.

However, given the explicit contraindication noted in guidelines and the availability of effective alternatives, the non-GLP-1 options remain appropriate for your situation 1.

Treatment Algorithm

Step 1: Cardiovascular and Psychiatric Screening

• Assess for cardiovascular disease history, uncontrolled hypertension, seizure disorders, and current opiate use 1.
• Screen for depression and smoking cessation needs 1.

Step 2: Medication Selection Based on Comorbidities

• If you have migraines: Prioritize phentermine-topiramate ER 1.
• If you have depression or are attempting smoking cessation: Consider naltrexone-bupropion ER 1.
• If you have cardiovascular disease or seizure history: Use orlistat 1.
• If no specific comorbidities: Start with phentermine-topiramate ER for maximum efficacy 1.

Step 3: Combine with Lifestyle Interventions

• All anti-obesity medications must be combined with lifestyle modifications including dietary changes and physical activity 1.
• Multicomponent behavioral interventions with at least 14 sessions over 6 months optimize outcomes 1.
• Weight loss of 5-10% improves blood pressure by approximately 3 mm Hg and may decrease hemoglobin A1c by 0.6-1% if you have diabetes 1.

Step 4: Long-Term Management

• Anti-obesity medications generally need to be used chronically for sustained weight loss 1.
• Maintaining long-term weight loss is difficult, and guidelines support continued medication use when weight maintenance is inadequate with lifestyle interventions alone 1.

Common Pitfalls to Avoid

• Do not discontinue cardiovascular medications that may cause weight gain (like certain antidepressants or antihyperglycemics) without discussing alternatives with your physician first 1.
• Ensure regular blood pressure and heart rate monitoring if using phentermine-containing medications or naltrexone-bupropion ER 1.
• Do not expect medication alone to produce sustained weight loss—the combination with behavioral interventions is essential 1.